Co-Authors
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and SENTHIL DAMODARAN.
Connection Strength
1.556
-
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 01; 42(19):2281-2294.
Score: 0.240
-
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.
Score: 0.233
-
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer. 2023 Aug 11; 9(1):66.
Score: 0.229
-
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
Score: 0.223
-
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
Score: 0.194
-
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
Score: 0.178
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.158
-
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
Score: 0.058
-
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol. 2019 10; 92:32-38.
Score: 0.043